medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2008, Number 2

Next >>

Rev Mex Patol Clin Med Lab 2008; 55 (2)

High-sensitive protein C-reactive, a marker of cardiovascular risk

Capelini F, Durazo QF

Language: Spanish
References: 14
Page: 55-58
PDF size: 88.80 Kb.


ABSTRACT

Given the current life expectancy, 77 years in males and 81 in females, and the prevalence of cardiovascular disease in adults as a cause of death, multiple efforts have been made to identify and prevent atherosclerotic disease at its earliest stages. The purpose of this paper is to analyze the results of ultra sensitive C-reactive protein (usCRP) in a group of adult individuals of both genders who presented at the lab in fasting to undergo a lipid profile and usCRP determination. A total of 1,595 individuals were included, with a mean age of 59 years. The lipid profile (total cholesterol, triglycerides, HDL, LDL, and atherogenic index) and usCRP were measured using Beckman-Coulter hardwer. The results were interpreted in accordance with the lipid profile guidelines of the National Cholesterol Education Program (NCEP) and the Adult Treatment Panel III (ATP III), and the American Heart Association (AHA) usCRP guidelines. It was found that 20.5% (327) of the individuals had usCRP levels within the high-risk range (3.1-10.0 mg/L) and lipid levels within the ranges recommended by the NCEP. The current endothelial dysfunction concept is analyzed, as well as the importance of usCRP as a predictive parameter of cardiovascular disease.


REFERENCES

  1. Vega GE. Calidad de vida en la vejez. Foro Académico en Problemas de salud global. Academia N de Medicina 2008.

  2. Dawber TR, Moore FE Jr, Mann GV. Coronary heart disease in the Framingham Study. Am J Public Health 1957; 47: 4-24.

  3. Boletín de Información Clínica Terapéutica Ac N de Med 2005: XIV (5).

  4. Bula LM, Willerson JT. Role of Inflammation in coronary plaque disruption. Circulation 1994; 89: 503-505.

  5. Rader D. Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1178-1182.

  6. Ridker PM. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.

  7. Koening W et al. C-reactive protein modulates risk prediction based on the Framingham score. Circulation 2004; 109: 1349-1353.

  8. Pearson TA et al. New AHA/CDC Guidelines Support the use of usCRP Testing in Intermediate Risk CVD Patients. Circulation 2003; 107: 499-511.

  9. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high sensitivity C-reactive protein and Lipid screen. Clin Chem 2001; 47 (1): 28-30.

  10. Nissen SE et al. Statin therapy, LDL cholesterol, C-reactive protein and coronary artery disease. N Engl J Med 2005; 352: 29-38.

  11. Panel de Expertos del Programa Nacional de Educación en Colesterol (NCEP). JAMA 2001; 285: 2486-2497.

  12. III Panel de tratamiento en el Adulto (ATP III). J Clin Hypertens 2001; 3: 292-295.

  13. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high sensitivity C-reactive protein and lipid screen. Clin Chem 2001; 47(1): 28-30.

  14. Ajani U et al. Prevalence of High-C reactive protein in persons with FERUM lipid concentration within recommended values. Clin Chem 2004; 50 (9): 1618-1622.




2020     |     www.medigraphic.com